Condition: Non Hodgkin's Lymphoma Refractory/Relapsed · Sponsor: ImmunityBio, Inc.
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.
This description comes directly from the study's public registry record.
Mark Nelson · 213 414 3566 · mark.nelson@immunitybio.com
Atessa Kiani · 9499038749 · atessa.kiani@immunitybio.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital | Newport Beach, California, United States | Recruiting |
| Texas Oncology | Tyler, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05618925